Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NE3107 Activity and Safety in Parkinson's Disease
NCT05083260Phase 2Completed
- Sponsor
- BioVie
- Start
- Jan 2022
- Primary completion
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Parkinson's disease (PD) comparing NE3107 Arm with Placebo Arm (2 arms). Primary endpoints: Change from baseline in Motor Disease Society-Unified Parkinson's Disease Rating Scale Part III total score in the 'off-state' at Day 28, Change from baseline in the length of time during which L-dopa therapy is ineffective (OFF time) and 11 more. Started Jan 2022; status: completed.
02
Drugs
bezisterim
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT05083260.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05083260.